|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/14/21 Cell MedX Corp. 10-Q 11/30/20 53:2M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 286K
2: EX-10.30 Loan Agreement and Note Payable Dated September 2, HTML 19K
2020, Among Cell Medx Corp. and Rain
Communications Corp.
3: EX-10.31 Loan Agreement and Note Payable Dated October 26, HTML 20K
2020, Among Cell Medx Corp. and Rain
Communications Corp.
4: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
14: R1 Document and Entity Information HTML 64K
15: R2 Condensed Consolidated Balance Sheets HTML 82K
16: R3 Condensed Consolidated Balance Sheets - HTML 23K
Parenthetical
17: R4 Condensed Consolidated Statements of Operations HTML 74K
18: R5 Condensed Consolidated Statement of Stockholders' HTML 60K
Deficit
19: R6 Condensed Consolidated Statements of Cash Flows HTML 83K
20: R7 Organization and Nature of Operations HTML 22K
21: R8 Related Party Transactions Disclosure HTML 31K
22: R9 Inventory Disclosure HTML 18K
23: R10 Other Current Assets Disclosure HTML 18K
24: R11 Equipment Disclosure HTML 23K
25: R12 Revenue Disclosure HTML 26K
26: R13 Notes and Advances Payable Disclosure HTML 38K
27: R14 Share Capital Disclosure HTML 40K
28: R15 Related Party Transactions Disclosure: Schedule of HTML 24K
Amounts Due to Related Parties (Tables)
29: R16 Related Party Transactions Disclosure: Schedule of HTML 22K
Transactions with Related Parties (Tables)
30: R17 Equipment Disclosure: Change in book value of the HTML 22K
equipment (Tables)
31: R18 Revenue Disclosure: Schedule of Revenue and HTML 26K
Associated Costs (Tables)
32: R19 Notes and Advances Payable Disclosure: Schedule of HTML 33K
Short-term Loans and Advances Outstanding (Tables)
33: R20 Share Capital Disclosure: Schedule of Stock Option HTML 24K
Activity (Tables)
34: R21 Share Capital Disclosure: Schedule of Stock HTML 22K
Options Outstanding (Tables)
35: R22 Share Capital Disclosure: Schedule of Warrant HTML 24K
Activity (Tables)
36: R23 Share Capital Disclosure: Schedule of Warrant HTML 23K
Details (Tables)
37: R24 Organization and Nature of Operations (Details) HTML 20K
38: R25 Related Party Transactions Disclosure: Schedule of HTML 33K
Amounts Due to Related Parties (Details)
39: R26 Related Party Transactions Disclosure: Schedule of HTML 26K
Transactions with Related Parties (Details)
40: R27 Inventory Disclosure (Details) HTML 21K
41: R28 Other Current Assets Disclosure (Details) HTML 20K
42: R29 Equipment Disclosure: Change in book value of the HTML 26K
equipment (Details)
43: R30 Revenue Disclosure: Schedule of Revenue and HTML 35K
Associated Costs (Details)
44: R31 Notes and Advances Payable Disclosure: Schedule of HTML 44K
Short-term Loans and Advances Outstanding
(Details)
45: R32 Notes and Advances Payable Disclosure (Details) HTML 34K
46: R33 Share Capital Disclosure (Details) HTML 29K
47: R34 Share Capital Disclosure: Schedule of Stock Option HTML 26K
Activity (Details)
48: R35 Share Capital Disclosure: Schedule of Stock HTML 28K
Options Outstanding (Details)
49: R36 Share Capital Disclosure: Schedule of Warrant HTML 25K
Activity (Details)
50: R37 Share Capital Disclosure: Schedule of Warrant HTML 33K
Details (Details)
52: XML IDEA XML File -- Filing Summary XML 89K
51: EXCEL IDEA Workbook of Financial Reports XLSX 44K
8: EX-101.INS XBRL Instance -- cmxc-20201130 XML 553K
10: EX-101.CAL XBRL Calculations -- cmxc-20201130_cal XML 60K
11: EX-101.DEF XBRL Definitions -- cmxc-20201130_def XML 235K
12: EX-101.LAB XBRL Labels -- cmxc-20201130_lab XML 436K
13: EX-101.PRE XBRL Presentations -- cmxc-20201130_pre XML 372K
9: EX-101.SCH XBRL Schema -- cmxc-20201130 XSD 100K
53: ZIP XBRL Zipped Folder -- 0001393905-21-000010-xbrl Zip 51K
| ex-31.1 |
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Frank McEnulty, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2020, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: January 14, 2021
/s/ Frank McEnulty
Chief Executive Officer
(Principal Executive Officer)
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 1/14/21 | None on these Dates | ||
| For Period end: | 11/30/20 | |||
| List all Filings | ||||